Home / Pharmaceutical company intelligence
Panacea Pharmaceuticals logo
Pharmaceutical company intelligence

Panacea Pharmaceuticals

Pharmaceutical manufacturer · Islamabad · Pakistan

Islamabad/Rawat pharmaceutical manufacturer producing tablets, liquids, ointments and injectables for the national market.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date20 Aug 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Panacea Pharmaceuticals Pakistan
Company type
Pharmaceutical manufacturer
Address
Plot 4, Street S-6, National Industrial Zone, Rawat, Islamabad, Pakistan
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000600 Panacea Pharmaceuticals. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000600 111 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx113public portfolio records represented
REG90unique registrations represented
IDX111indexed MedInfoBase presentations
SRC2additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR111current validated price records
G43generic molecules in indexed catalogue
DF7dosage-form groups
TA10therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage98%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage96%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixPanacea PharmaceuticalsShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/panacea-pharmaceuticalsGenerated 23 Sep 2026Anti-infectives61 · 55%CNS & mental health24 · 22%Gastrointestinal & hepatology7 · 6%Cardiovascular4 · 4%Hematology & thrombosis4 · 4%Vitamins, minerals & nutrition3 · 3%Reproductive & genitourinary2 · 2%Other therapeutic areas6 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioPanacea PharmaceuticalsDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/panacea-pharmaceuticalsGenerated 23 Sep 2026111presentationsTablet64 · 58%Capsule20 · 18%Suspension14 · 13%Drops5 · 5%Cream4 · 4%Gel3 · 3%Other forms1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionPanacea PharmaceuticalsCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/panacea-pharmaceuticalsGenerated 23 Sep 2026107comparable productsBelow peer median21 · 20%Near peer median43 · 40%Above peer median43 · 40%Company median price position+4.2%Lowest-price equivalents8Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsPanacea PharmaceuticalsCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/panacea-pharmaceuticalsGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,32 shared74% overlapCCL Pharmaceuticals (Pvt.) Limited28 shared65% overlapHIGH-Q Pharmaceuticals28 shared65% overlapGenome Pharmaceuticals (Pvt.) Ltd.28 shared65% overlapM/s. Genix Pharma (Pvt) Ltd.27 shared63% overlapBosch Pharmaceuticals (Pvt) Ltd.26 shared60% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives61 products · 55%
CNS & mental health24 products · 22%
Gastrointestinal & hepatology7 products · 6%
Cardiovascular4 products · 4%
Hematology & thrombosis4 products · 4%
Vitamins, minerals & nutrition3 products · 3%
Reproductive & genitourinary2 products · 2%
Ophthalmology2 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antipsychotics16 products · 14%
Fluoroquinolone antibacterials15 products · 14%
Macrolide antibacterials13 products · 12%
Antimalarials9 products · 8%
Antifungals7 products · 6%
Proton pump inhibitors6 products · 5%
Antiparasitic medicines4 products · 4%
Third-generation cephalosporins4 products · 4%
Formulation footprint

Dosage forms

Tablet64 products
Capsule20 products
Suspension14 products
Drops5 products
Cream4 products
Gel3 products
Injection1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 QUTECQuetiapine 7presentations 100 mg, 200 mg, 25 mg · Tablet #2 NEEDOXCiprofloxacin 5presentations 0.3 %, 125 mg/5 mL, 250 mg, 250 mg/5 mL · Drops, Suspension, Tablet #3 ZITHINAzithromycin 5presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Tablet #4 APROClarithromycin 4presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet #5 GAMPOmeprazole 4presentations 20 mg, 40 mg · Capsule #6 LEVINLevofloxacin 4presentations 125 mg/5 mL, 250 mg, 500 mg, 750 mg · Suspension, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2120% of comparable products
Near market median43within ±5% of median
Above market median4340% of comparable products
Lowest-price equivalents8ties included
Company median price position +4.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
METRONOL 0.75 %Metronidazole (Benzoate) · Gel · 15gm PKR 5.35/g-74.8% vs market median METRONOL 0.75 %Metronidazole (Benzoate) · Gel · 25gm PKR 5.78/g-72.8% vs market median NEEDOX 125 mg/5 mLCiprofloxacin · Suspension · 60ml PKR 2.00/mL-43.5% vs market median NEEDOX 250 mg/5 mLCiprofloxacin · Suspension · 60ml PKR 3.44/mL-33.5% vs market median AMEPINE 5 mgAmlodipine · Tablet · 20 PKR 7.23/tablet-33.4% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 32shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 28shared generics HIGH-Q Pharmaceuticals215 products · 61 generics 28shared generics Genome Pharmaceuticals (Pvt.) Ltd.181 products · 84 generics 28shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 27shared generics Bosch Pharmaceuticals (Pvt) Ltd.258 products · 74 generics 26shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers89Distinct registrations among indexed, published, presentation-validated products only
Verified price observations222
Products with a verified price111
Products with multiple price observations111
Source records with multiple versions111
Latest portfolio source check22 Sep 2026
Latest effective price date20 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

90 unique registration(s) · 111 indexed presentation(s) · 2 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
AMEPINE Amlodipine 10 mg Tablet 20 081427 PKR 299.47 PKR 14.97/tablet 16% below median
AMEPINE Amlodipine 5 mg Tablet 20 111590 PKR 144.52 PKR 7.23/tablet 33% below median
APRO Clarithromycin 500 mg Tablet 10 045927 PKR 919.06 PKR 91.91/tablet 10% above median
APRO Clarithromycin 250 mg Tablet 10 045928 PKR 495.67 PKR 49.57/tablet Near median
APRO Clarithromycin 125 mg/5 mL Suspension 60ml 072756 PKR 460.56 PKR 7.68/mL Near median
APRO Clarithromycin 250 mg/5 mL Suspension 60ml 072960 PKR 817.86 PKR 13.63/mL 13% above median
Artemef Artemether + Lumefantrine 20 mg + 120 mg Tablet 16 046478 PKR 660.90 PKR 41.31/tablet 5% above median
Artemef Artemether + Lumefantrine 40 mg + 240 mg Tablet 8 056334 PKR 545.24 PKR 68.16/tablet 6% above median
Artemef DS Artemether + Lumefantrine 80 mg + 480 mg Tablet 6 060132 PKR 681.55 PKR 113.59/tablet Near median
Artemef DS Artemether + Lumefantrine 80 mg + 480 mg Tablet 4 060132 PKR 454.37 PKR 113.59/tablet Near median
ATISER Lorazepam 1 mg Tablet 100 063384 PKR 152.42 PKR 1.52/tablet 24% above median
ATISER Lorazepam 2 mg Tablet 100 063385 PKR 187.18 PKR 1.87/tablet 20% above median
CALINOL PLUS Clindamycin 1 % Gel 10gm 072771 PKR 475.02 PKR 47.50/g 175% above median
CALINOL-V w/w Clindamycin 2 % Cream 40gm 072768 PKR 541.41 PKR 13.54/g No comparator
CARBPAN Ascorbic acid 500 mg Tablet 40 106071 PKR 48.18 PKR 1.20/tablet 21% below median
CLAP Clopidogrel 75 mg Tablet 10 050183 PKR 289.14 PKR 28.91/tablet 6% above median
CLAP Clopidogrel + Aspirin 75 mg + 75 mg Tablet 10 059433 PKR 299.47 PKR 29.95/tablet 5% above median
CLOZTEC Clozapine 25 mg Tablet 50 054956 PKR 1,652.24 PKR 33.04/tablet Near median
CLOZTEC Clozapine 100 mg Tablet 50 054957 PKR 3,614.28 PKR 72.29/tablet Near median
CO TELSART Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet 14 075020 PKR 640.24 PKR 45.73/tablet Near median
DIZILAM Midazolam 7.5 mg Tablet 10 063387 PKR 103.27 PKR 10.33/tablet 9% below median
Etec Eacht Entecavir 0.5 mg Tablet 30 069953 PKR 21,066.10 PKR 702.20/tablet 97% above median
FLUXELEX Fluoxetine 20 mg Capsule 30 047788 PKR 386.63 PKR 12.89/capsule Near median
FLUXELEX Fluoxetine 20 mg Capsule 10 047788 PKR 134.24 PKR 13.42/capsule Near median
GAMP Omeprazole 20 mg Capsule 14 044644 PKR 297.40 PKR 21.24/capsule 8% above median
GAMP Omeprazole 20 mg Capsule 10 044644 PKR 218.92 PKR 21.89/capsule 11% above median
GAMP Omeprazole 40 mg Capsule 14 054943 PKR 516.33 PKR 36.88/capsule 6% above median
GAMP Omeprazole 40 mg Capsule 10 054943 PKR 369.69 PKR 36.97/capsule 7% above median
ITROPAN Itraconazole 100 mg Capsule 4 047773 PKR 619.59 PKR 154.90/capsule 7% above median
KUNSIV Clomifene citrate 50 mg Tablet 20 099863 PKR 679.81 PKR 33.99/tablet 19% below median
KUNSIV Clomifene citrate 50 mg Tablet 10 099863 PKR 346.84 PKR 34.68/tablet 17% below median
LANPER Latanoprost 0.005 % Ophthalmic drops 2.5ml 072765 PKR 795.14 PKR 318.06/mL 6% above median
LEDOPID Linezolid 600 mg Tablet 12 099751 PKR 4,104.24 PKR 342.02/tablet 13% below median
LEDOPIF Linezolid 100 mg/5 mL Dry suspension 60mL 099752 PKR 562.00 PKR 9.37/mL 13% below median
LETRODRX Letrozole 2.5 mg Tablet 10 099750 PKR 4,130.61 PKR 413.06/tablet Near median
LETRODRX Letrozole 2.5 mg Tablet 30 099750 PKR 12,391.83 PKR 413.06/tablet Near median
LEVIN Levofloxacin 500 mg Tablet 10 044641 PKR 859.17 PKR 85.92/tablet 9% above median
LEVIN Levofloxacin 250 mg Tablet 10 044642 PKR 516.33 PKR 51.63/tablet 8% above median
Levin Levofloxacin 750 mg Tablet 10 054952 PKR 1,032.65 PKR 103.27/tablet 11% above median
LEVIN Levofloxacin 125 mg/5 mL Dry suspension 60ml 075031 PKR 309.80 PKR 5.16/mL Near median
LOSTEC Loratadine 10 mg Tablet 30 056337 PKR 428.26 PKR 14.28/tablet Near median
LOSTEC Loratadine 10 mg Tablet 10 056337 PKR 148.70 PKR 14.87/tablet Near median
LUMETHER DS Artemether + Lumefantrine 80 mg + 480 mg Capsule 6 060131 PKR 681.55 PKR 113.59/capsule Near median
LUMETHER DS Artemether + Lumefantrine 80 mg + 480 mg Capsule 4 060131 PKR 454.37 PKR 113.59/capsule Near median
LUMETHER FORTE Artemether + Lumefantrine 40 mg + 240 mg Capsule 8 060130 PKR 545.24 PKR 68.16/capsule 8% above median
MAGSER Omeprazole 20 mg Tablet 14 059426 PKR 297.40 PKR 21.24/tablet 12% above median
MAGSER Omeprazole 40 mg Tablet 14 060286 PKR 516.33 PKR 36.88/tablet 14% above median
Mectin Ivermectin 3 mg Tablet 20 075025 PKR 660.90 PKR 33.05/tablet Near median
Mectin Ivermectin 6 mg Tablet 10 075026 PKR 547.30 PKR 54.73/tablet Near median
METRONOL Metronidazole (Benzoate) 0.75 % Gel 25gm 111086 PKR 144.52 PKR 5.78/g 73% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Panacea Pharmaceuticals — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/panacea-pharmaceuticals/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.